Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma

Fig 5

Cost-effective scatter plot.

Results of Monte Carlo probabilistic sensitivity analysis showing incremental cost-effective of finotonlimab plus bevacizumab biosimilar versus sorafenib.

Fig 5

doi: https://doi.org/10.1371/journal.pone.0349044.g005